Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease
- PMID: 19448533
- DOI: 10.1097/MOG.0b013e32832bc627
Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease
Abstract
Purpose of review: This review focuses on CD4+ T cells involved in the mediation of inflammatory tissue damage in murine models of inflammatory bowel diseases (IBDs). In particular, we describe the distinct roles of the homeostatic cytokine IL-7, which is essential to the maintenance of colitogenic memory CD4+ cells, and the newly discovered effector cytokine IL-17. We also discuss the close correlation between colitogenic Th17-type CD4+ T cells and inducible CD4+CD25+Foxp3+ regulatory T cells.
Recent findings: IBDs are characterized by wasting and chronic intestinal inflammation induced by many different cytokine-mediated pathways. It is clearly recognized that medical and surgical interventions do not cure Crohn's disease because relapse is the rule after remission. Until a few years ago, IBD was classified into Th1-dependent, that is, Crohn's disease, and Th2-dependent, that is, ulcerative colitis, phenotypes. However, in recent years, it has been shown that new T-cell subclasses, that is, Th17 and regulatory T cells (T(R)), exist independently of Th1 and Th2 and that they play a central role in modulating IBD.
Summary: The persistence of IL-7-dependent colitogenic memory CD4+ T cells is critical to the maintenance of experimental colitis. On the other hand, though Th1 and Th2 colitogenic memory CD4+ cells exist, in recent years the central role of IL-17-producing Th17-type cells in IBD has attracted renewed interest. The development of molecularly targeted therapies aimed at a variety of different Th-dependent pathogenic mechanisms may represent a novel approach to IBD therapy.
Similar articles
-
Long-lived colitogenic CD4+ memory T cells residing outside the intestine participate in the perpetuation of chronic colitis.J Immunol. 2009 Oct 15;183(8):5059-68. doi: 10.4049/jimmunol.0803684. Epub 2009 Sep 28. J Immunol. 2009. PMID: 19786550
-
Targeting the development and effector functions of TH17 cells.Semin Immunol. 2007 Dec;19(6):383-93. doi: 10.1016/j.smim.2007.10.016. Epub 2008 Jan 14. Semin Immunol. 2007. PMID: 18083530 Review.
-
Bone marrow retaining colitogenic CD4+ T cells may be a pathogenic reservoir for chronic colitis.Gastroenterology. 2007 Jan;132(1):176-89. doi: 10.1053/j.gastro.2006.10.035. Epub 2006 Oct 25. Gastroenterology. 2007. PMID: 17241870
-
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice.Gastroenterology. 2007 Jun;132(7):2359-70. doi: 10.1053/j.gastro.2007.03.104. Epub 2007 Apr 13. Gastroenterology. 2007. PMID: 17570211
-
After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?Int Immunopharmacol. 2007 Apr;7(4):409-16. doi: 10.1016/j.intimp.2006.09.024. Epub 2006 Nov 13. Int Immunopharmacol. 2007. PMID: 17321463 Review.
Cited by
-
The IL-27/IL-27R axis is altered in CD4+ and CD8+ T lymphocytes from multiple sclerosis patients.Clin Transl Immunology. 2021 Mar 5;10(3):e1262. doi: 10.1002/cti2.1262. eCollection 2021. Clin Transl Immunology. 2021. PMID: 33728050 Free PMC article.
-
Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa.J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1116-1127. doi: 10.1002/jcsm.12449. Epub 2019 Jul 15. J Cachexia Sarcopenia Muscle. 2019. PMID: 31307125 Free PMC article.
-
Curcumin Anti-Apoptotic Action in a Model of Intestinal Epithelial Inflammatory Damage.Nutrients. 2017 Jun 6;9(6):578. doi: 10.3390/nu9060578. Nutrients. 2017. PMID: 28587282 Free PMC article.
-
Analysis of the association of single nucleotide polymorphisms of interleukin-23 receptor (IL-23R) and inflammatory bowel disease in a Chinese Han cohort.Oncotarget. 2016 Oct 18;7(42):67851-67856. doi: 10.18632/oncotarget.12296. Oncotarget. 2016. PMID: 27765927 Free PMC article.
-
IL-17 and IL-22 genetic polymorphisms in HBV vaccine non- and low-responders among healthcare workers.Germs. 2016 Mar 1;6(1):14-20. doi: 10.11599/germs.2016.1084. eCollection 2016 Mar. Germs. 2016. PMID: 27019828 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials